Objectives: Lenalidomide, a hazardous drug, has strict distribution controls. However, the risk of contamination with lenalidomide when patients take the drug has not been studied and the risk of drug exposure to people in the patient's living environment is unknown. Thus, we investigated the amount of lenalidomide that could be dispersed during the period between removal of the capsule and returning the used blister packages, and we considered the conditions under which lenalidomide could be dispersed and countermeasures.

Methods: The amount of lenalidomide contamination was measured on the outside of the unused blister packages returned by the patients, on the surface of the capsule, and on the inside of the package immediately after removal of the capsule. In addition, the amount of contamination was measured on the blister packages used by the patients and on the gloves worn by the pharmacists on receipt of the packages. Lenalidomide was analysed by liquid chromatography-tandem mass spectrometry.

Results: Lenalidomide amounts on the outside of the unused blister packages returned by the three patients were <10, <10, and 26.8 ng/pack, those on the capsule surface immediately after removal from the packages were 297, 388, and 297 ng/capsule, and those on the inside of packages immediately after removal of all capsules were 143, 184, and 554 ng/pack, respectively. A median of 15.6 ng/pack lenalidomide was detected on the surface of packages used by the patients (n=18). The lenalidomide remaining in the packages immediately after capsule removal (~200 ng/pack), except for the 15.6 ng/pack detected in the packages used by the patients, may have been dispersed in the patient's living environment (~90% or more). The maximum amount of lenalidomide on the surface of the packages used by the patients was over 2500 ng/pack.

Conclusions: The amount of lenalidomide contamination per package was found to be at least 100 ng less after collection by the pharmacist than immediately after removal of the capsules. Therefore, it is recommended to clean the surrounding area and wash one's hands after taking the capsules.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11672486PMC
http://dx.doi.org/10.1136/ejhpharm-2022-003632DOI Listing

Publication Analysis

Top Keywords

blister packages
16
lenalidomide
8
amount lenalidomide
8
lenalidomide dispersed
8
removal capsule
8
contamination measured
8
unused blister
8
packages returned
8
packages
5
risk exposure
4

Similar Publications

Objectives: To explore nursing home (NH) staff's experiences implementing an automated blister packaging system for solid, orally ingestible drugs.

Design: This was a descriptive qualitative study. Semistructured interviews were used for data collection, and qualitative content analysis was applied for data analysis.

View Article and Find Full Text PDF

Pharmaceutical packaging is essential for enhancing the storage stability of medicine and can improve medication adherence and usability. Despite their widespread use, blister packs can be challenging to use, especially when pushing out the medication. This study investigates how specific cavity characteristics of blister packs can enhance usability for spherical capsules, which are harder to push out than tablets.

View Article and Find Full Text PDF

Safe medication delivery is an essential component of medical care in the overnight summer camp setting, especially for children with cancer and medical complexity. Blister packaging of medications is a method that may improve safety in this setting. In this quality improvement project, we implemented and evaluated a system of on-site blister packaging of medications with the goal of optimizing the safety and efficiency of medication delivery at a large overnight summer camp for children with cancer.

View Article and Find Full Text PDF

Paper waste and carbon emissions from oral contraceptive leaflets.

PLoS One

October 2024

IVF unit, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Faculty of Health Science and Medicine, Tel Aviv University, Tel Aviv, Israel.

Oral contraceptives (OC) are the most used form of contraception among women in the U.S. and Europe.

View Article and Find Full Text PDF

Background: The opioid epidemic has severely impacted the US over the last 15 years. Buprenorphine is a partial opioid agonist indicated for the treatment of opioid use disorder (OUD) and is recognized as an effective treatment when taken as prescribed. However, adherence rates have been low in real-world settings.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!